For those noble individuals who equate money with sin, Agios (NASDAQ:AGIO) offers a sublime opportunity to watch capital evaporate. Agios is one of the beneficiaries of the frothy market for biotech IPOs, having raised more than $100 million in its IPO in July 2013. Shares have soared after the biotech sell-off last autumn, rising 150% since the November low of $15.77. At a market cap of $1.3 billion, Agios has already joined the big leagues. The only problem is that none of the company's drug prospects have moved beyond phase 1 trials. With the market already pricing in a greater than 100% likelihood of success for AGIO's lead compound AG-348, investors can only lose by owning AGIO stock....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|